<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442676</url>
  </required_header>
  <id_info>
    <org_study_id>VCU IRB HM10590</org_study_id>
    <nct_id>NCT00442676</nct_id>
  </id_info>
  <brief_title>Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia</brief_title>
  <official_title>Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia is a hypertensive disorder of pregnancy and a leading cause of fetal and
      maternal morbidity and mortality. Recent findings indicate preeclampsia is an inflammatory
      disorder associated with increased expression of COX-2. This study will test the hypothesis
      that treatment of women with a COX-2 inhibitor, celecoxib, will stop the inflammatory process
      and reverse symptoms of preeclampsia.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients were recruited. Treatment drug expired.
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length from start of treatment to delivery</measure>
    <time_frame>From start of treatment to delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of severe preeclampsia</measure>
    <time_frame>From start of treatment to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From start of treatment to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>From start of treatment to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal complications</measure>
    <time_frame>From start of treatment to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal/neonatal status</measure>
    <time_frame>From start of treatment to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>At time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>At time of delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib, 200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Capsule, 200 mg/day until 32 weeks of gestation</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelatin capsules of lactose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with preeclampsia between 20 - 32 weeks gestation. Preeclampsia is
             defined as a maternal blood pressure of &gt;140/90 mmHg on two readings at least 6 hours
             apart with proteinuria of &gt;300 mg/24 hours.

        Exclusion Criteria:

          -  Exclusion criteria includes patients with known sensitivity to celecoxib; patients who
             have demonstrated allergic-type reactions to sulfonamides; patients who have
             experienced asthma, urticaria, or allergic-type reactions after taking aspirin or
             other NSAIDs. Other exclusion criteria will include patients with known cardiovascular
             disease or risk factors for cardiovascular disease, a prior history of ulcer disease
             or GI bleeding, impaired renal function, or liver dysfunction. Exclusion criteria will
             also include concomitant use of oral corticosteroids, anticoagulants, diuretics, ACE
             inhibitors, aspirin, fluconazole, and lithium.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott W Walsh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan M Lanni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fidelma B Rigby, MD</last_name>
    <role>Study Director</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole W Karjane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MCV Main Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shah TJ, Walsh SW. Activation of NF-kappaB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. Am J Obstet Gynecol. 2007 Jan;196(1):48.e1-8.</citation>
    <PMID>17240230</PMID>
  </reference>
  <reference>
    <citation>Leik CE, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension. 2004 Jul;44(1):72-7. Epub 2004 May 17.</citation>
    <PMID>15148293</PMID>
  </reference>
  <reference>
    <citation>Groom KM, Shennan AH, Jones BA, Seed P, Bennett PR. TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. BJOG. 2005 Jun;112(6):725-30.</citation>
    <PMID>15924527</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

